Aclarion Inc
Healthcare · USD
Price
$3.41
Cap
$8M
Earnings
2/4 beat
30d Trend
-4%
Near 52-week lows — potential value or falling knife
Target range: $7 – $7 (consensus: $7)
Consensus: Strong Buy
Earnings history
Q4 2025
BEAT
-2.01 vs -3.28
Q3 2025
MISS
-2.93 vs -2.64
Q2 2025
MISS
-2.75 vs -2.26
Q1 2025
BEAT
-9.32 vs -1447.19
Key macro factors
Global economic growth and consumer spending on healthcare, indirectly affected by the Middle East conflict and potential IMF downgrades, could impact demand for Aclarion's solutions.
Market adoption and insurance reimbursement pathways for novel healthcare technologies like Nociscan are crucial for Aclarion's commercial success and scalability.
Regulatory approval hurdles and intense competitive pressures within the health information services sector pose ongoing challenges for Aclarion's growth and market position.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.